New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program

Abstract

A common tool for detecting mild cognitive impairment (MCI) is the Montreal Cognitive Assessment (MoCA). An extension of the standard MoCA testing – MoCA-Memory Index Score (MoCA-MIS; Memory Index, MI) – allows a deeper study of the mechanisms of MCI formation. We consider the drug Prospecta as an effective measure to prevent the progression of MCI. Objective : to study the efficacy and safety of Prospecta in the treatment of MCI in patients with cerebrovascular disease (CVD) in real clinical practice. Material and methods . The observational program PRIORITET included 192 patients of both sexes aged 40 to 74 years inclusive (mean age 63.6±8.8 years) with MCI and CVD, they were prescribed Prospecta, two tablets twice a day during 24 weeks. The presence of MCI was confirmed by testing on the MoCA scale; MI was assessed additionally`. At the end of treatment, the condition of patients was assessed using the Overall Clinical Impression Scale and the safety of the therapy. Results . The change in the mean score on the MoCA scale after 24 weeks of therapy with Prospecta was 5.3 (p<0.0001). The proportion of patients who responded positively to treatment with Prospecta and after 24 weeks of treatment restored their cognitive functions to normal (MoCA >26 points), reached 48.9%. Additionally, patients were divided into groups depending on the results of testing on the MoCA scale and MI. During therapy with Prospecta, the number of patients in the MIS <7 and MoCA <20 group decreased by 19 times, in the MIS <7 or MoCA <20 group – by 4.8 times. There were 16 adverse events, 75% of which were mild. In 62.5% of adverse events, there was no connection with taking Prospecta. Conclusion . Prospecta is an effective and safe treatment for patients with MCI and CVD.